Moreover, elevated serum levels of SFRP2 are associated with poor prognosis and metastasis in breast cancer patients, in which the SFRP2 promoter is, similar to prostate cancer, hypermethylated in the primary cancer side [23]. Here, SFRP2 is linked to prostate cancer.